BRIEF-EMA Advises Continued Use Of Medicines For Hypertension, Heart Or Kidney Disease During COVID-19 Pandemic - Reuters Discover Thomson Reuters FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters Directory of sites Login Contact Support Business Markets World Politics TV More United States Healthcare March 27, 2020 / 3:56 PM / Updated an hour ago BRIEF-EMA Advises Continued Use Of Medicines For Hypertension, Heart Or Kidney Disease During COVID-19 Pandemic 1 Min Read March 27 (Reuters) - European Medicines Agency: * ADVISES CONTINUED USE OF MEDICINES FOR HYPERTENSION, HEART OR KIDNEY DISEASE DURING COVID-19 PANDEMIC * CURRENTLY NO EVIDENCE FROM CLINICAL/EPIDEMIOLOGICAL STUDIES THAT ESTABLISHES LINK BETWEEN ACE INHIBITORS OR ARBS AND WORSENING OF COVID-19 * SCIENTIFIC RESEARCH ONGOING TO UNDERSTAND SARS-COV-2, WHETHER ONGOING TREATMENT WITH MEDICINES SUCH AS ACE-INHIBITORS, ARBS COULD IMPACT PROGNOSIS Source text for Eikon: [ID: bit.ly/39pvxmO] Our Standards:The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and-landscape-tablet medium-wide-browser-and-larger above-phone portrait-tablet-and-above above-portrait-tablet landscape-tablet-and-above landscape-tablet-and-medium-wide-browser portrait-tablet-and-below landscape-tablet-and-below Apps Newsletters Advertise with Us Advertising Guidelines Cookies Terms of Use Privacy All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Â© 2020 Reuters. All Rights Reserved.